The "Goldilocks" Dose: Why Precision Matters with Hydroxychloroquine

If you have lupus, hydroxychloroquine (HCQ)—often known by the brand

name Plaquenil—is likely the cornerstone of your treatment. In the lupus

community, we often call it "the lupus life insurance" because it reduces flares,

protects organs and even extends life expectancy.

However, in 2026, the conversation around HCQ has shifted from "everyone

should take 5 mg/kg per day or less" to a much more precise, personalized

approach. Because with this drug, the difference between a life-saving dose

and a potentially toxic one comes down to a few milligrams, and regular

testing.

1. The Weight-Based Math

For decades, many patients were prescribed a flat dose of 400mg per day.

Since 2016, the American Academy of Ophthalmology recommended weight-

based dosing. The reasoning for this is that in a Kaiser Permanente study,

doses above 5 mg/kg/d had a greater risk for eye damage (called retinopathy):

• The 5mg Rule: Current clinical guidelines recommend a maximum daily

  dose of 5mg/per kg of real body weight.

• Using this recommendation, proper dosing for someone weighing 135 to

  175 pounds, the recommended dose would be approximately 300 mg

  daily. Those weighing less than 135 pounds should be on around 200 mg

  daily, while those above 175 pounds should be on 400 mg daily.

• 400 mg daily being considered the maximum recommended dose.

• However, this weight-based approach did not take into account the

  effectiveness of this dosing recommendation (it underdoses many lupus

  patients who are poor absorbers of HCQ).

2. The Danger of "Retinopathy"

The most serious risk of long-term HCQ use is retinopathy—damage to the

retina at the back of the eye.

• The "Silent" Phase: In the early stages, HCQ toxicity has zero symptoms.

  You won't notice blurry vision or blind spots. By the time you do notice a

  change in your vision, the damage is often permanent and irreversible.

• The Cumulative Risk: The risk is low in the first 5 years (under 1%), but it

  jumps to roughly 20% after 20 years of treatment.

3. Why Testing is Your Best Defense

In 2026, managing HCQ is a team sport between you, your rheumatologist,

and your ophthalmologist. There are two types of "testing" that are non-

negotiable:

A. The High-Tech Eye Exam

Standard eye charts aren't enough. You need specialized imaging:

• SD-OCT (Optical Coherence Tomography): A "cross-section" 3D map of

  your retina that can see microscopic thinning before your vision changes.

• Fundus Autofluorescence: A specialized camera that looks for "stress" in the retinal cells.

• Automated Visual Field Test: This checks your "perimetry" (peripheral

  vision) for tiny blind spots. This is now only recommended if FAF or OCT

  are not available in your area.

B. Blood Level Monitoring (The New Standard)

In 2026, more rheumatologists are ordering Whole Blood HCQ Blood Level

Tests.

• It is important to ensure that the HCQ drug level result does not say

  “serum” or “plasma.” If so, then the wrong test was done in the lab. A

  serum or plasma HCQ drug level will underestimate the result and will

  make it look like a patient is not taking their medication, and be

  incorrectly labeled as “nonadherent” by their rheumatologist.

• Checking for Absorption: Some people’s bodies process the drug very

  quickly (as much as 87% of a dose), while others absorb it slowly (as low

  as 61% of a dose). A blood test ensures you are in the "therapeutic and

  safe window"

• Aiming for the right drug level target: A recent article recommends that

  rheumatologists aim for a whole blood of 750 to 1150 ng/mL. Levels of

  750 ng/mL or higher are associated with better disease control, while

  levels below 1150 ng/mL are associated with a reduced risk of HCQ-

  induced retinopathy. This way, doctors can prescribe a more

  appropriate dose of HCQ by adjusting it based on blood level results.

• Blindly dosing by body weight (5 mg/kg/d) can increase the risk for

  retinopathy for someone with a high absorption rate. In those who are

  poor absorbers of HCQ, dosing by body weight can result in low HCQ

  drug levels, leading to an increased chance of increased lupus disease

  activity and more lupus flares.

• Checking for Adherence: Sometimes, the lab shows the drug isn't in the

  system at all. This helps doctors figure out whether a flare is due to the

  drug not working or to missed doses.

“If we measure thoughtfully, communicate empathetically, and titrate deliberately, we can potentially deliver safer, more effective, and optimal HCQ dosing.” -Shivani Garg, MD

Summary Checklist for 2026

Action Item	Frequency	Why?
Weight Check	Every Rheumatology visit	To ensure your dose stays in the safe zone.
Baseline Eye Exam	Within 1 year of starting	To get a "before" picture of your retinal health.
Annual Eye Imaging	Every year after Year 5	To catch "silent" toxicity early.
HCQ Blood Level	Once a year (or during flares)	To confirm the dose is actually in the "Goldilocks" zone.

To help you verify the latest medical standards for hydroxychloroquine (HCQ) as of 2026, here are the primary sources and clinical guidelines referenced in the blog.

2026 Clinical Guidelines & Standards

• Arthritis Care & Research Editorial: Toward Optimal Dosing in Systemic

  Lupus Erythematosus: The Case for Hydroxychloroquine Blood Level

  Monitoring

  • Makes the case for using HCQ blood level dosing instead of

    weight-based dosing: “The current state: weight-based dosing alone

    is not ‘enough’ or ‘optimal’”

• American Academy of Ophthalmology (AAO) 2026 Revision: Revised Recommendations on Screening for Hydroxychloroquine Retinopathy

  • The gold-standard guide for 2026, detailing the refined 5 mg/kg real-weight dosing limit and the expansion of risk factors to include initiation at age 45+.

• Healio Rheumatology (Jan 2026): Study Identifies Optimal HCQ Blood Level Range

  • Reports the new consensus that the therapeutic "Goldilocks zone" for blood levels is 750 to 1,150 ng/mL, helping to prevent both flares and toxicity.

• Ophthalmology Journal (April 2026): Updated Screening Recommendations Refine HCQ Dosage

  • A summary of the high-impact study justifying annual SD-OCT and Fundus Autofluorescence (FAF) imaging as the primary tools for catching early retinal thinning.

In closing:

If the prescriber is dosing correctly with the new clinical guidelines and standards, and you are taking HCQ as prescribed, this medication is the ONLY drug proven to ensure a healthier future. Take it from me, I have been on HCQ for over 25 years, and it saved my life.

Compiled By:

Kelli (Casas) Roseta

Medically Reviewed and Edited By:

Donald Thomas, MD, FACP, FACR, Author of The Lupus Encyclopedia

https://www.amazon.com/Lupus-Encyclopedia-Comprehensive-Patients-Providers/dp/1421446847/ref=tmm_pap_swatch_0?_encoding=UTF8&qid=&sr=

Sources:

Balevic Stephen J (Orcid ID: 0000-0002-4016-1680)

Title: Toward Optimal Dosing in SLE: The Case for Hydroxychloroquine Blood Level Monitoring, Authors: Stephen Balevic MD PhD1, Donald Thomas MD2, Shivani Garg MD PhD https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr.80020

https://pmc.ncbi.nlm.nih.gov/articles/PMC11364994/#:~:text=Recent%20studies%20have%20demonstrated%20that,risk%20of%20disease%20flare%2Dups

hydroxychloroquine for lupus

Long-Term Hydroxychloroquine Therapy and Risk of Coronary Artery Disease in Patients with Systemic Lupus Erythematosus

Hydroxychloroquine and Cardiovascular Events in Patients With Systemic Lupus Erythematosus - PMC

Hydroxychloroquine in patients with systemic lupus erythematosus: how much is enough? | Lupus Science & Medicine

Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge - PMC